

NPAIHB COVID-19 Weekly Update

Please sign in using the chat box:

Enter the tribe or organization you are representing
and names of all people participating with you today



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

Information for Today's Call

Agenda

- Welcome & Introduction: Chairman Lewis
- NPAIHB COVID-19 Situation Report: Celeste Davis
- Indian Health Service Update: Dean Seyler
- FEMA Update: Jay Laplante
- State Partner Updates:
 - Washington: Lou Schmitz, Tamara Fife, Jessie Dean, and Tam Lutz
 - Oregon: Julie Johnson, Candice Jimenez, and Sue Steward
 - Idaho: Joyce Broadsword, Liz Coronado, and Jessica Leston
- Legislative and Policy Update: Liz Coronado and Candice Jimenez

Guidelines

- Please place yourself on mute unless speaking
- Sign in, using chat box, with your tribe/organization and names of all participants
- Use the chat box for questions, for Q&A after updates and announcements



NPAIHB COVID-19 Situation Report

Celeste Davis



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

C-19 Emergency Response - NPAIHB Situation Report: 3/2/21

We Can Do It

Wear a mask, maintain distance, avoid crowds, wash hands

- Case rates continue to trend downward
- Monitor Community Immunity
- Increase Testing – best tool for detecting and protecting
 - **Use testing strategies to reopen schools and child care centers**
- Continue Vaccination Ramp-up
 - **3rd Vaccine Approved!**
 - **Health care worker vaccinations – training from Dr. Weiser**
 - **Make sure to use auto “opt in” approach**





COVID-19 Vaccine Review



Prepared by the Northwest Portland Area Indian Health Board (NPAIHB)

Updated 3/1/2021



Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
How it works	Messenger RNA	Messenger RNA	Inactivated Adeno-virus base (Non-replicating vector vaccine)	Inactivated Adeno-virus base (Non-replicating vector vaccine)	Protein-based (recombinant nanoparticle tech)
Date approved/ Expected approval	December 11, 2020	December 18, 2020	February 27, 2021	Has not submitted application for EUA in U.S. yet, but possibly in April	Has not submitted application for EUA in U.S. yet. Currently in phase 3 clinical trials
Efficacy in preventing COVID-19 related hospitalization and death	All five vaccines (Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax) have demonstrated efficacy in preventing severe COVID-19 disease, hospitalizations and deaths. Out of 75,000 people who have received these vaccines as part of research studies, <u>no one</u>, has died from COVID-19.				

Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
What percentage of people did it protect from getting infected in clinical studies?	95% efficacy to prevent symptomatic COVID-19 infection after 2 doses	94.1% efficacy to prevent symptomatic COVID-19 infection after 2 doses; 86.4% for those ≥ 65	66-72% efficacy to prevent symptomatic COVID-19 infection after 1 dose; 85% efficacy in preventing severe disease	70.4% efficacy to prevent symptomatic COVID-19 infection after 2 doses	89.3% efficacy to prevent symptomatic COVID-19 infection after 2 doses in UK, 85.6% for B.117 strain
How many shots do you need?	Two doses, 3 weeks (or 21 days) apart	Two doses, 4 weeks (or 28 days) apart	One dose	Two doses, 4 weeks (or 28 days) apart	Two doses, 3 weeks (or 21 days) apart
What are the potential side effects?	Fatigue, headache, chills, muscle aches, especially after the second dose	Fever, muscle aches, headaches lasting a few days. Effects worse after second dose	Fatigue, headache, muscle aches, nausea and injection site pain	Injection site pain, fever, muscle aches, headache	Fatigue, headache, muscle aches and injection site pain
Storage	-112°F to -76°F (before mixing, vaccine may be stored at 36°F to 46°F for up to 120 hours or 5 days)	-13°F to 5°F (vaccine vials may be stored at 36°F to 40°F for 1 month or 30 days)	36° to 46°F (may be stored at 36° to 46°F for at least 3 months)	36°F to 46°F (may be stored at 36°F to 46°F for at least 6 months)	36°F to 46°F (ready to use)



Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
Who can receive this vaccine?	16 years and older	18 years and older	18 years and older	18 years and older	18 years and older
What about pregnant and breastfeeding women?	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. mRNA vaccines are not thought to be a risk to the breastfeeding infant	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. mRNA vaccines are not thought to be a risk to the breastfeeding infant	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor.	The vaccine has not yet been studied in pregnant or lactating women. Pregnant women are allowed to get the vaccine, but should first consult with their doctor. The vaccine is not considered to be a risk to the breastfeeding infant	Not yet available
Who should not get this vaccine?	Caution and consultation should be taken with persons who have a history of serious allergic reactions. Contraindicated in people with prior reactions to vaccine ingredients	Caution and consultation should be taken with persons who have a history of serious allergic reactions. Contraindicated in people with prior reactions to vaccine ingredients	Contraindicated in people with prior reactions to vaccine ingredients	The vaccine should not be given to those who have had a previous severe allergic reaction to a previous dose of the same COVID-19 vaccine or an ingredient in the COVID-19 vaccine	Not yet available

Vaccine developer:	Pfizer	Moderna	Johnson & Johnson	AstraZeneca	Novavax
Any significant side effects?	During December 14–23, 2020, there were 21 cases of anaphylaxis after the first dose. 4 cases of Bell's palsy in clinical trial vaccine group	During December 21, 2020–January 10, 2021, there were 10 cases of anaphylaxis after the first dose. 3 cases of Bell's palsy in clinical trial vaccine group	One case of hives and swelling of the lips, one case of severe pain in the injected arm, and one case of generalized weakness, fever, and headache	Four total serious adverse events, including one case of transverse myelitis	Not yet available
What about people with lowered immune function and autoimmune diseases?	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Ok for people whose immune function is lowered by HIV, immunosuppressing drugs, or autoimmune disease. People with these conditions may still get the vaccine if they have no other contraindications. There is limited safety data in this group	Not yet available	Not yet available



Indian Health Service Update

Dean Seyler



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

FEMA Update

Jay Laplante, Region X Tribal Liaison



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

State Partner Updates

Washington AIHC/DOH/HCA: Lou Schmitz, Tamara Fife, Jessie Dean, and Tam Lutz

Oregon OHA: Julie Johnson, Candice Jimenez, and Sue Steward

Idaho DHW: Joyce Broadsword, Liz Coronado, and Jessica Leston



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

Legislative and Policy Update

March 2, 2021

Liz Coronado and Candice Jimenez

virtual



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health

Legislative and Policy Update Agenda

- Happenings on The Hill
- Hearings on The Hill
- New and Pending Federal Policy Changes
- Upcoming Events
- Upcoming Regional and National Meetings



Happenings on The Hill

- **Biden's American Rescue Plan**

- \$20 billion in aid to tribal governments
 - \$1 billion divided equally
 - \$19 billion as determined by the Secretary of the Treasury
- \$6.094 billion for tribal health programs
 - \$2 billion for lost revenue
- 100% FMAP for Urban Indian Health Organizations (two years)
- 100% FMAP for Native Hawaiian Health Care Systems (two years)

- **H.R. 1047 – Expand broadband service to rural/tribal communities**

- **H.R. 1065 – Eliminate discrimination and promote women's health/economic security at work**

- **H.R. 1373 – Extend 100% FMAP to Urban Indian Organizations**

- **H.R. 1332/S.368 – Make Telehealth Flexibilities Permanent**

- **S.421 – Expand the Indian Reservation Drinking Water Program**



Hearings on The Hill

- **Senate Energy and Natural Resources Committee**

- Held two confirmation hearings regarding Representative Deb Haaland's nomination as Hearing for Interior Secretary last week
- Business meeting scheduled for Mar 4 at 10am ET to consider Rep. Haaland's nomination.

- **Senate Finance Committee**

- Voting on the nomination Xavier Becerra as Health and Human Services Secretary on Mar 4, 2021



New and Pending Federal Policy Changes

- **Center for Indigenous Innovation and Health Equity**

- Request for Information from the Office of Minority Health
- Proposed Center focused on health research, policy and innovation
- Comments due by Mar 14, 2021

- **CMS 1135 Waivers** – public comment on process improvements

- Proposed streamlined, automated process for providers to submit information
- Comments due by Mar 22, 2021

- **Enforcement Discretion-** web-based scheduling applications

- OCR exercising its enforcement discretion for noncompliance with HIPAA for web-based scheduling applications being used for COVID-19 vaccine scheduling. Effective 12/11/2020.



Upcoming Events

- **National Indian Health Board – Medicaid Managed Care Listening Session**
 - Mar 4, 2021 from 11:00am – 1:00pm
 - Tribal Health Directors, Tribal business office staff should attend
 - There will be presentations on:
 - Indian specific protections that managed care organizations are supposed to follow
 - CMS Resources
 - Portland Area and Oklahoma Area challenges/successes with managed care
 - And a facilitated discussion regarding your questions, problems, and concerns
 - This listening session will help determine the agenda for a Spring 2021 Managed Care Roundtable



Upcoming Regional & National Meetings

Mar 04	NIHB Managed Care Listening Session
Mar 09	Tribal Leaders Diabetes Committee Email Veronica at vsmith-contractor@npaihb.org with any issues re SDPI
Mar 10 – 11	CMS Tribal Technical Advisory Group Email Liz at ecoronado@npaihb.org or Veronica vsmith-contractor@npaihb.org with any issues for the TTAG
Mar 16 – 18	Purchased/Referred Care Workgroup Email Veronica at vsmith-contractor@npaihb.org with PRC issues
Mar 18	HHS Region 10 Tribal Call Email Liz at ecoronado@npaihb.org or Candice at cjimenez@npaihb.org to bring issues forward



Questions or Comments



[This Photo](#) by Unknown Author is licensed under [CC BY-SA](#)



NORTHWEST PORTLAND AREA
INDIAN HEALTH BOARD
Indian Leadership for Indian Health